Prostate cancer originates in the male prostate gland and has become one of the most common types of cancer. It typically remains confined in this region, however it may spread to other locations throughout the body. Risk of prostate cancer increases with age, family history, obesity, and ethnicity as black males are the most likely to develop prostate cancer. Treatment for prostate cancer includes radiation therapy, hormone therapy, surgery, and chemotherapy. Hormone refractory prostate cancer occurs when various hormone therapies fail to prevent the development of the prostate cancer. This failure can occur for various amounts of time, ranging from months or years after therapy has began. Occasionally, stopping the androgen blockade and introducing testosterone into the blood stream may help with preventing tumor growth. However, fear of hormone refractory prostate cancer is the cancer will spread, thus the next step typically includes chemotherapy drugs.
Top Research Reagents
We have 6581 products for the study of Hormone Refractory Prostate Cancer that can be applied to Chromatin Immunoprecipitation (ChIP), Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot from our catalog of antibodies and ELISA kits.